Home > For Consumers > Azithromycin versus penicillin G...

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2003-. doi: 10.1002/14651858.CD007270.pub2

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet].

Azithromycin versus penicillin G benzathine for early syphilis

This version published: 2012; Review content assessed as up-to-date: November 28, 2011.

Link to full article: [Cochrane Library]

Plain language summary

Syphilis is a complex disease that can involve virtually any organ in the body. The World Health Organization estimates that at least 12 million people are infected with syphilis worldwide. Some early research suggested that azithromycin was superior to benzathine penicillin G in the treatment of early syphilis, and that azithromycin can overcome the disadvantages of penicillin G benzathine. This review of three trials failed to identify a difference between azithromycin and benzathine penicillin G for early syphilis in the odds of cure rate, with the result being too imprecise to confidently rule out the superiority of either treatment option. Although gastrointestinal adverse effects were more common in the participants on azithromycin, than in those given benzathine penicillin G, the difference with benzathine penicillin did not reach statistical significance. More research is required in this area.

Abstract

Background: Syphilis is a complex systemic disease caused by a spirochete, Treponema pallidum. The World Health Organization estimates that at least 12 million people worldwide are currently infected with syphilis. In this review we compared two current standards of treatment for early syphilis, benzathine benzylpenicillin (penicillin G) and azithromycin.

Objectives: To evaluate the efficacy and safety of azithromycin versus benzathine penicillin (penicillin G) for early syphilis.

Search methods: We searched the following databases using the search terms detailed in Appendix 1: the Cochrane Sexually Transmitted Diseases Group Specialized Register (July 2011), the Cochrane Central Register of Controlled Trials (CENTRAL) published in The Cochrane Library (Issue 7 2011), MEDLINE (1948 to July 2011), EMBASE (1980 to July 2011), PsycINFO (1806 to July 2011) and the Chinese Biological Medicine Literature Database (CBM) (1978 to 2011). The search was not limited by language.

Selection criteria: Randomized controlled trials comparing azithromycin with benzathine penicillin G at any dose for the treatment of early syphilis.

Data collection and analysis: Two review authors independently applied the inclusion criteria to potential studies, with any disagreements resolved by discussion. The risk of bias of each study was assessed by the same two review authors. We pooled data using an odds ratio (OR).

Main results: Three studies (generating four eligible study comparisons) were included. One study is ongoing. There was no statistically significant difference between azithromycin and benzathine penicillin treatment in the odds of cure (OR 1.04, 95% CI 0.69 to 1.56); nor any difference at three months (OR 0.97, 95% CI 0.62 to 1.50), six months (OR 1.09, 95% CI 0.76 to 1.54) or nine months (OR 1.45, 95% CI 0.46 to 6.42). Subgroup analysis by primary and latent syphilis and by dose of azithromycin (2 g and 4 g) did not explain the variation between the study results. The reporting of computed mild to tolerated adverse events, from two included trials, indicated no statistically significant difference between azithromycin and benzathine penicillin (OR 1.43, 95% CI 0.42 to 4.95), although with a high level of heterogeneity (P = 0.05, I2 = 74%).

Authors' conclusions: Differences in the odds of cure did not reach statistical significance when azithromycin was compared with benzathine penicillin for the treatment of early syphilis. No definitive conclusion can be made regarding the relative safety of benzathine penicillin G and azithromycin for early syphilis. Further studies on the utility of benzathine penicillin G for early syphilis are warranted.

Editorial Group: Cochrane Sexually Transmitted Infections Group.

Publication status: New.

Citation: Bai ZG, Wang B, Yang K, Tian JH, Ma B, Liu Y, Jiang L, Gai QY, He X, Li Y. Azithromycin versus penicillin G benzathine for early syphilis. Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No.: CD007270. DOI: 10.1002/14651858.CD007270.pub2. Link to Cochrane Library. [PubMed: 22696367]

Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PMID: 22696367

Download

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...